Firsocostat is an acetyl-CoA carboxylase inhibitor that functions in the liver. Its original designation was GS-0976.[1] It was discovered by Nimbus Therapeutics.[2] The drug is under development by Gilead as a treatment for non-alcoholic fatty liver disease.[3]

References

  1. ^ Alkhouri, Naim; Lawitz, Eric; Noureddin, Mazen; DeFronzo, Ralph; Shulman, Gerald I. (1 February 2020). "GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)". Expert Opinion on Investigational Drugs. 29 (2): 135–141. doi:10.1080/13543784.2020.1668374. PMC 7063378. PMID 31519114.
  2. ^ Harriman, Geraldine; Greenwood, Jeremy; Bhat, Sathesh; Huang, Xinyi; Wang, Ruiying; Paul, Debamita; Tong, Liang; Saha, Asish K.; Westlin, William F.; Kapeller, Rosana; Harwood, H. James (29 March 2016). "Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats". Proceedings of the National Academy of Sciences. 113 (13): E1796-805. Bibcode:2016PNAS..113E1796H. doi:10.1073/pnas.1520686113. PMC 4822632. PMID 26976583.
  3. ^ Alkhouri, Naim (1 February 2020). "NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges". Expert Opinion on Investigational Drugs. 29 (2): 87. doi:10.1080/13543784.2020.1721169. PMID 31984804. S2CID 210924006.